IL302112A - Novel anti-cd47 antibodies and uses thereof - Google Patents

Novel anti-cd47 antibodies and uses thereof

Info

Publication number
IL302112A
IL302112A IL302112A IL30211223A IL302112A IL 302112 A IL302112 A IL 302112A IL 302112 A IL302112 A IL 302112A IL 30211223 A IL30211223 A IL 30211223A IL 302112 A IL302112 A IL 302112A
Authority
IL
Israel
Prior art keywords
antibody
cell
cancer
seq
immunologically active
Prior art date
Application number
IL302112A
Other languages
English (en)
Hebrew (he)
Inventor
Zhengyi Wang
Wei Cao
Bingshi Guo
Cong Xu
Original Assignee
I Mab Biopharma Co Ltd
Zhengyi Wang
Wei Cao
Bingshi Guo
Cong Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd, Zhengyi Wang, Wei Cao, Bingshi Guo, Cong Xu filed Critical I Mab Biopharma Co Ltd
Publication of IL302112A publication Critical patent/IL302112A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL302112A 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof IL302112A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CN2020122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL302112A true IL302112A (en) 2023-06-01

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302112A IL302112A (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Country Status (12)

Country Link
US (1) US20230399400A1 (https=)
EP (1) EP4229088A1 (https=)
JP (1) JP2023546277A (https=)
KR (1) KR20230114745A (https=)
CN (1) CN116348601A (https=)
AU (1) AU2021360633A1 (https=)
CA (1) CA3198895A1 (https=)
CO (1) CO2023005611A2 (https=)
IL (1) IL302112A (https=)
MX (1) MX2023004223A (https=)
TW (1) TW202229351A (https=)
WO (1) WO2022078465A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) * 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof
WO2019091473A1 (en) * 2017-11-10 2019-05-16 I-Mab Biopharma Co., Ltd. Fusion proteins containing cd47 antibodies and cytokines
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines

Also Published As

Publication number Publication date
WO2022078465A1 (en) 2022-04-21
KR20230114745A (ko) 2023-08-01
EP4229088A1 (en) 2023-08-23
TW202229351A (zh) 2022-08-01
US20230399400A1 (en) 2023-12-14
MX2023004223A (es) 2023-08-03
AU2021360633A9 (en) 2025-01-09
CA3198895A1 (en) 2022-04-21
CO2023005611A2 (es) 2023-05-29
JP2023546277A (ja) 2023-11-01
CN116348601A (zh) 2023-06-27
AU2021360633A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US11485782B2 (en) Anti-claudin 18.2 antibodies
US12458818B2 (en) Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
JP7523219B2 (ja) Ｃｔｌａ－４に対する単一ドメイン抗体及びその変異体
EP3774917B1 (en) Single-domain antibodies against lag-3 and uses thereof
AU2018366650A1 (en) Single-domain antibodies and variants thereof against PD-L1
KR20250107971A (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
WO2021047599A1 (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
JP7377185B2 (ja) 抗ヒトｔｌｒ７抗体
IL302112A (en) Novel anti-cd47 antibodies and uses thereof
US20250101120A1 (en) Antibodies specifically recognizing fasl and uses thereof
JP2025519056A (ja) Ｋｌｒｂ１結合剤及びその使用方法
WO2025119313A1 (en) Novel anti-cd47 antibodies and uses thereof
HK40091237A (zh) 新型抗cd47抗体及其用途
AU2023401113A1 (en) Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
JP2023523919A (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
HK40075187A (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
HK40034257B (en) Anti-claudin 18.2 antibodies
HK40034257A (en) Anti-claudin 18.2 antibodies
BR112020006860A2 (pt) composição para depleção de células t citotóxicas